Butyrate Lowers Cellular Cholesterol through HDAC Inhibition and Impaired SREBP-2 Signalling

In animal studies, HDAC inhibitors such as butyrate have been reported to reduce plasma cholesterol, while conferring protection from diabetes, but studies on the underlying mechanisms are lacking. This study compares the influence of butyrate and other HDAC inhibitors to that of statins on choleste...

Descripción completa

Detalles Bibliográficos
Autores principales: Bridgeman, Stephanie, Woo, Hon Chiu, Newsholme, Philip, Mamotte, Cyril
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779842/
https://www.ncbi.nlm.nih.gov/pubmed/36555149
http://dx.doi.org/10.3390/ijms232415506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779842/
https://www.ncbi.nlm.nih.gov/pubmed/36555149
http://dx.doi.org/10.3390/ijms232415506

Ejemplares similares